TrivarX Limited
TRI.AX
Australian Securities Exchange0.02
AUD
+0.00
- -
TrivarX Limited
TRI.AX
(Australian Securities Exchange)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- TrivarX Limited (TRI.AX) engages in the development and commercialization of AI-driven, scientifically based devices and software for screening and diagnosing behavioral health conditions, with a focus on sleep and autonomic nervous system metrics. The company operates primarily through its software-as-a-service platform and related medical devices designed to analyze physiological signals for mental health assessment. TrivarX maintains a two-country footprint, with operational presence in Australia and the United States, and maintains a corporate structure centered on research, development, and commercial deployment of its health technology offerings. The company was founded in 2010 and is headquartered in Frankfurt am Main, Germany, positioning itself to serve global markets through strategic partnerships and regulatory-compliant product launches. Core capabilities include proprietary algorithms for spectral analyses of sleep architecture and heart rate variability, enabling products that identify depression and other mental health conditions from physiological data. Primary product categories comprise AI-powered diagnostic devices, cloud-based data analytics platforms, and subscription-based access to clinical decision-support tools for healthcare providers and enterprise clients. TrivarX’s ecosystem emphasizes clinical research-backed technology, with ongoing collaboration initiatives aimed at expanding validation studies, refining diagnostic accuracy, and broadening application across behavioral health care settings. Recent corporate activity highlights include strategic partnerships with healthcare institutions and technology firms to scale deployment in target markets, ongoing development of enhanced SaaS offerings, and expanded commercial outreach in the US and Australian markets. The company maintains a focus on enterprise and clinical customers, including healthcare providers, research organizations, and corporate health programs, as it scales its AI-driven screening solutions globally.